| http://purl.uniprot.org/citations/28749773 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/28749773 | http://www.w3.org/2000/01/rdf-schema#comment | "Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in Plasmodium vivax malaria. This open-label, dose-escalation study assessed quantitatively the hemolytic risk with tafenoquine in female healthy volunteers heterozygous for the Mahidol487A glucose-6-phosphate dehydrogenase (G6PD)-deficient variant versus G6PD-normal females, and with reference to primaquine. Six G6PD-heterozygous subjects (G6PD enzyme activity 40-60% of normal) and six G6PD-normal subjects per treatment group received single-dose tafenoquine (100, 200, or 300 mg) or primaquine (15 mg × 14 days). All participants had pretreatment hemoglobin levels ≥ 12.0 g/dL. Tafenoquine dose escalation stopped when hemoglobin decreased by ≥ 2.5 g/dL (or hematocrit decline ≥ 7.5%) versus pretreatment values in ≥ 3/6 subjects. A dose-response was evident in G6PD-heterozygous subjects (N = 15) receiving tafenoquine for the maximum decrease in hemoglobin versus pretreatment values. Hemoglobin declines were similar for tafenoquine 300 mg (-2.65 to -2.95 g/dL [N = 3]) and primaquine (-1.25 to -3.0 g/dL [N = 5]). Two further cohorts of G6PD-heterozygous subjects with G6PD enzyme levels 61-80% (N = 2) and > 80% (N = 5) of the site median normal received tafenoquine 200 mg; hemolysis was less pronounced at higher G6PD enzyme activities. Tafenoquine hemolytic potential was dose dependent, and hemolysis was greater in G6PD-heterozygous females with lower G6PD enzyme activity levels. Single-dose tafenoquine 300 mg did not appear to increase the severity of hemolysis versus primaquine 15 mg × 14 days."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.org/dc/terms/identifier | "doi:10.4269/ajtmh.16-0779"xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Narayan S."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Miller A."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Mohamed K."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Luzzatto L."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Kleim J.P."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Qureshi A."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Green J.A."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Bancone G."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Duparc S."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Nosten F.H."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Beelen A.P."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Harrell E.J."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Kongpatanakul S."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Mohrle J.J."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Rousell V."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Rueangweerayut R."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/author | "Yubon N."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/date | "2017"xsd:gYear |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/name | "Am J Trop Med Hyg"xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/pages | "702-711"xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/title | "Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers."xsd:string |
| http://purl.uniprot.org/citations/28749773 | http://purl.uniprot.org/core/volume | "97"xsd:string |